<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Case 1: A 26-year-old female was admitted because of <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> with 43.6% myeloblasts and 33.6% monocytes, and trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (T-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) was detected on bone marrow (BM) smear </plain></SENT>
<SENT sid="1" pm="."><plain>She was diagnosed as having <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (M4) with T-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and was treated with the Japan Adult <z:hpo ids='HP_0001909'>Leukemia</z:hpo> Study Group (JALSG) AML87 protocol </plain></SENT>
<SENT sid="2" pm="."><plain>After completion of chemotherapy, leukemic myeloblasts remained minimally and myelodysplastic changes were still detected on BM smear </plain></SENT>
<SENT sid="3" pm="."><plain>She underwent allo-BMT from an HLA-identical sibling </plain></SENT>
<SENT sid="4" pm="."><plain>The conditioning regimen consisted of <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> A and short term <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were administered prophylactically for <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="6" pm="."><plain>She developed slight <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> and <z:hpo ids='HP_0001876'>pancytopenia</z:hpo>, which improved soon </plain></SENT>
<SENT sid="7" pm="."><plain>She is surviving free of disease for 37 months from BMT </plain></SENT>
<SENT sid="8" pm="."><plain>Case 2: A 41-year-old male was diagnosed as having T-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (M2) and achieved complete remission with the AML89 protocol, but relapsed soon </plain></SENT>
<SENT sid="9" pm="."><plain>He underwent allo-BMT from an HLA-identical sibling </plain></SENT>
<SENT sid="10" pm="."><plain>The conditioning regimen and prophylaxis against GVHD were the same as in case 1 </plain></SENT>
<SENT sid="11" pm="."><plain>He developed mild <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD, <z:hpo ids='HP_0002202'>pleural effusion</z:hpo> and later mild <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="12" pm="."><plain>These improved soon </plain></SENT>
<SENT sid="13" pm="."><plain>He is surviving free of disease for 21 months from BMT </plain></SENT>
<SENT sid="14" pm="."><plain>Some reports suggest that intensive chemotherapy can induce CR in 40%-70% of patients with T-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, but most of them tend to relapse and rarely survive long </plain></SENT>
<SENT sid="15" pm="."><plain>We consider that the best strategy for treatment of T-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is allo-BMT at present, if suitable donors are available </plain></SENT>
</text></document>